Clinical impact of sentinel lymph node biopsy after neoadjuvant systemic treatment in luminal B, HER-2 positive and triple-negative breast cancer patients with initially involved axillary lymph node(s) : Protocol for prospective, non-randomised, observational clinical trial
Libri Oncologici Croatian Journal of Oncology · 2019
DOI: 10.20471/lo.2019.47.01.06 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Libri Oncologici Croatian Journal of Oncology, 2019. Verfasst von Ana Car Peterko und 5 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Peterko, A. C., Avirović, M., Mance, D., Zujić, P. V., Lovasić, I. B., & Lovasić, F. (2019). Clinical impact of sentinel lymph node biopsy after neoadjuvant systemic treatment in luminal B, HER-2 positive and triple-negative breast cancer patients with initially involved axillary lymph node(s) : Protocol for prospective, non-randomised, observational clinical trial. Libri Oncologici Croatian Journal of Oncology. https://doi.org/10.20471/lo.2019.47.01.06
Vancouver
Peterko AC, Avirović M, Mance D, Zujić PV, Lovasić IB, Lovasić F. Clinical impact of sentinel lymph node biopsy after neoadjuvant systemic treatment in luminal B, HER-2 positive and triple-negative breast cancer patients with initially involved axillary lymph node(s) : Protocol for prospective, non-randomised, observational clinical trial. Libri Oncologici Croatian Journal of Oncology. 2019. doi:10.20471/lo.2019.47.01.06
BibTeX
@article{Peterko2019,
author = {Peterko, Ana Car and Avirović, Manuela and Mance, Diana and Zujić, Petra Valković and Lovasić, Ingrid Belac and Lovasić, Franjo},
title = {Clinical impact of sentinel lymph node biopsy after neoadjuvant systemic treatment in luminal B, HER-2 positive and triple-negative breast cancer patients with initially involved axillary lymph node(s) : Protocol for prospective, non-randomised, observational clinical trial},
journal = {Libri Oncologici Croatian Journal of Oncology},
year = {2019},
doi = {10.20471/lo.2019.47.01.06}
}
EUVIMED